Claims for Patent: 5,965,386

Summary for Patent: 5,965,386

Title:	Yeast strains and modified albumins
Abstract:	Albumin, for example human albumin, is expressed and secreted in yeast which has been mutated to lack the yeast aspartyl protease 3 (Yap3p) or its equivalent, thereby reducing the production of a 45 kD albumin fragment. A further reduction is achieved by additionally deleting the Kex2p function. Alternatively, a modified albumin is prepared which is not susceptible to Yap3p cleavage, for example human albumin which is R410A, K413Q and K414Q.
Inventor(s):	Kerry-Williams; Sean Martin (Nottingham, GB), Gilbert; Sarah Catherine (Oxford, GB)
Assignee:	Delta Biotechnology Limited (Nottingham, GB)
Application Number:	08/702,572
Patent Claims:	1. A process for preparing albumin comprising: genetically modifying yeast cells having a reduced level of yeast aspartyl protease 3 proteolytic activity of at most 50% as compared to the corresponding activity level of naturally-occurring yeast cells of the same kind, to produce and secrete albumin, and culturing said yeast cells in a culture medium such that albumin is secreted into said culture medium. 2. The process of claim 1 wherein said albumin is a human albumin. 3. The process of claim 1 wherein said yeast cells are S. cerevisiae. 4. The process of claim 3 wherein said yeast cells also have a reduced level of S. cerevisiae Kex2p proteolytic activity of at most 50% of the wild type level. 5. The process of claim 1 wherein said yeast cells lack a functional YAP3 gene or homologue thereof, wherein said homoloque has YAP3p-like roteolytic activity. 6. The process of claim 1 wherein said proteolytic activity is an endoprotease activity specific for monobasic sites and for paired basic amino acids in a polypeptide. 7. The process of claim 6 wherein said yeast cells are S. cerevisiae. 8. The process of claim 7 wherein said yeast cells additionally have a reduced level of S. cerevisiae Kex2p proteolytic activity of at most 50% of the wild type level. 9. The process of claim 6 wherein said yeast cells lack a functional YAP3 gene or homologue thereof, wherein said homologue has YAP3p-like proteolytic activity. 10. A culture of yeast cells having a reduced level of yeast aspartyl protease 3 proteolytic activity of at most 50% as compared to the corresponding activity level of naturally-occurring yeast cells of the same kind, containing a polynucleotide sequence encoding an albumin and a second polynucleotide sequence encoding a secretion signal causing albumin expressed from the first polynucleotide sequence to be secreted from the yeast. 11. The culture of claim 10 wherein said albumin is a human albumin. 12. The culture of claim 10 wherein said yeast cells are S. cerevisiae. 13. The culture of claim 12 wherein said yeast cells have a reduced level of S. cerevisiae Kex2p proteolytic activity of at most 50% of the wild type level. 14. The culture of claim 10 wherein said yeast cells lack a functional YAP3 gene or homologue thereof, wherein said homologue has YAP3p-like proteolytic activity. 15. The culture of claim 10 wherein said yeast cells have a reduced level of Kex2p proteolytic activity of at most 50% of the wild type level. 16. The culture of claim 10 wherein said signal is cleaved by said yeast cells prior to release of said albumin from said yeast cells. 17. The culture of claim 15 wherein said secretion signal is cleaved from said albumin by a protease other than Kex2p. 18. A modified albumin, which when expressed and secreted in yeast is non-susceptible to cleavage with yeast aspartyl protease 3 (YAP3p). 19. The modified albumin of claim 18 wherein said modified albumin lacks a monobasic amino acid present in said naturally occurring albumin protein. 20. The modified albumin of claim 18 wherein the said monobasic amino acid is arginine. 21. The modified albumin of claim 19 wherein said modified albumin additionally lacks a pair of basic amino acids present in the naturally-occurring albumin. 22. The modified albumin of claim 21 wherein said pair of amino acids is Lys, Lys; Lys, Arg; Arg, Lys; or Arg, Arg. 23. The modified albumin of claim 18 wherein said naturally-occurring albumin is a human albumin and the modified albumin lacks Arg.sup.410. 24. A modified albumin of claim 23 which is a human albumin having the amino acid changes R410A, K413Q, K414Q. 25. A polynucleotide encoding a modified albumin according to claim 18. 26. A yeast containing a polynucleotide according to claim 25 having transcription signals such that the modified albumin is expressed in the yeast, and a further polynucleotide adjacent the said polynucleotide such that said modified albumin is secreted from said yeast. 27. The modified albumin of claim 23 wherein residues 413 and 414 do not each consist of lysine or arginine.

Details for Patent 5,965,386

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942		2014-03-05
Baxalta Us Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	03/03/1954		2014-03-05
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	07/23/1976		2014-03-05
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	08/15/1978		2014-03-05